IGF-1: What This Test Actually Measures

What IGF-1 Actually Is

IGF-1 is a 70-amino-acid polypeptide produced mainly in the liver in response to growth hormone (GH) secreted by the anterior pituitary gland. The liver releases IGF-1 continuously, so its serum concentration stays relatively constant across the day. That stability is what makes it clinically useful: a single blood draw can reliably represent GH axis activity, something a direct GH measurement cannot do because GH is secreted in pulses every 3-5 hours and drops to undetectable levels between pulses.

The hormone works by binding to the IGF-1 receptor (IGF1R), a tyrosine kinase receptor expressed in muscle, bone, brain, and most other tissues. Once bound, IGF-1 drives cell proliferation, protein synthesis, and bone growth. In children, this signaling is responsible for linear height gain. In adults, it supports muscle protein turnover, bone mineral density maintenance, and metabolic regulation.

The GH-IGF-1 Axis: A Two-Step Signal

The pituitary releases GH in response to GHRH (growth hormone-releasing hormone) from the hypothalamus. GH then travels to the liver, where it binds GH receptors and triggers IGF-1 synthesis and secretion. IGF-1 then feeds back negatively on both the hypothalamus and pituitary to suppress further GH release. This closed loop means that measuring IGF-1 gives an indirect but integrated picture of how much GH the pituitary has been producing over the past several days, not just the past hour.

Why Serum IGF-1 Is Preferred Over Direct GH Measurement

Direct serum GH is nearly useless as a random screening test. Because GH pulses are episodic and short-lived, a random draw can show near-zero GH even in a person with acromegaly, simply because the sample was taken between pulses. IGF-1 averages out those pulses. The Endocrine Society's 2011 clinical practice guideline on acromegaly explicitly states that "IGF-1 measurement is the best single screening test for acromegaly" because of its stability and correlation with integrated 24-hour GH secretion. [1]

Normal IGF-1 Ranges by Age and Sex

IGF-1 levels are not static across a lifetime. They follow a predictable arc: low in infancy, rising sharply through puberty, peaking in the late teens to early twenties, then declining gradually with age. This means age- and sex-matched reference intervals must be used when interpreting any result.

Reference Intervals from Major Laboratories

Published reference data from large normative studies show the following approximate ranges. These figures come from the Endocrine Society guidelines and Mayo Clinic reference laboratory data cited in peer-reviewed literature [2]:

| Age Group | Approximate Range (ng/mL) | |-----------|--------------------------| | 5-9 years | 66-215 | | 10-14 years | 96-535 | | 15-19 years | 105-500 | | 20-24 years | 116-358 | | 25-39 years | 88-246 | | 40-54 years | 71-212 | | 55-69 years | 52-170 | | 70+ years | 37-140 |

These are approximate medians derived from normative populations. Individual laboratories use their own validated reference intervals, so a result should always be interpreted against the specific lab's own range, not universal thresholds.

Sex Differences

Women tend to have slightly higher IGF-1 values than age-matched men during reproductive years, likely because estrogen sensitizes liver GH receptors. After menopause, this difference narrows. Oral estrogen (but not transdermal) may lower IGF-1 by reducing hepatic GH sensitivity, an effect documented in trials comparing oral versus transdermal estrogen therapy. [3]

Age-Related Decline and Its Clinical Significance

After age 30, IGF-1 falls roughly 1-2% per year. By age 60, most adults have IGF-1 values 40-50% below their peak. Whether this decline causes symptoms or simply accompanies aging remains an active research area. A 2020 analysis published in the Journal of Clinical Endocrinology and Metabolism found that IGF-1 below the age-adjusted reference range was independently associated with reduced muscle strength and lower bone mineral density in adults over 60. [4]

What High IGF-1 Means

A high IGF-1 on an age- and sex-matched reference interval raises concern for excess GH secretion. The most common pathological cause is a GH-secreting pituitary adenoma, which produces acromegaly in adults and gigantism in children whose growth plates have not yet fused.

Acromegaly

Acromegaly affects approximately 60 people per million, with an estimated prevalence of 40-70 cases per million population. [5] The Endocrine Society 2014 acromegaly guidelines recommend confirming an elevated IGF-1 with an oral glucose tolerance test (OGTT): in healthy individuals, 75 g oral glucose suppresses GH to below 1 ng/mL within 1-2 hours; in acromegaly, this suppression fails. [1] Without treatment, acromegaly carries a 2-fold increase in all-cause mortality, largely from cardiovascular disease and sleep apnea. [5]

Exogenous GH Use

Recombinant human GH (somatropin, brand names Genotropin, Norditropin, Humatrope, Omnitrope) prescribed for adult GH deficiency is dosed to bring IGF-1 into the mid-normal range for age. Doses that push IGF-1 above the upper limit of normal constitute supraphysiologic GH exposure and are associated with fluid retention, carpal tunnel syndrome, and joint pain. The FDA-approved prescribing information for somatropin products explicitly recommends monitoring IGF-1 to avoid levels exceeding the normal range. [6]

IGF-1 and Cancer Risk

Elevated IGF-1 has been associated with modestly increased risk of several cancers, particularly colorectal and premenopausal breast cancer. A prospective analysis within the UK Biobank (N=392,928) published in BMC Medicine found that IGF-1 in the top quartile was associated with a 1.21-fold higher risk of colorectal cancer compared to the bottom quartile (95% CI 1.11-1.31, P<0.001). [7] This association does not establish that treating high IGF-1 reduces cancer risk, but it does inform the risk-benefit discussion around supraphysiologic GH supplementation.

What Low IGF-1 Means

Low IGF-1 reflects either inadequate GH production, impaired liver response to GH, or both. Each cause has different treatment implications, so low IGF-1 requires further testing rather than reflexive treatment.

Growth Hormone Deficiency

Adult GH deficiency (AGHD) produces a recognizable syndrome: increased visceral adiposity, decreased lean muscle mass, reduced bone mineral density, fatigue, and impaired quality of life. The Endocrine Society AGHD clinical practice guideline states: "Measurement of serum IGF-1 is useful in the initial diagnostic evaluation. A subnormal age-adjusted serum IGF-1 level is supportive evidence for AGHD but is not sufficient alone to establish the diagnosis." [8] Confirmatory stimulation testing (insulin tolerance test or GHRH-arginine test) is required before initiating GH replacement.

Non-Pituitary Causes of Low IGF-1

Several conditions lower IGF-1 independently of GH secretion:

• Liver disease: The liver produces IGF-1. Cirrhosis reduces hepatic GH receptor expression, producing low IGF-1 even with normal or elevated GH. A 2019 study in the Journal of Hepatology (N=312 patients with NAFLD-related cirrhosis) found mean IGF-1 of 54 ng/mL versus 147 ng/mL in matched controls. [9]
• Malnutrition: Caloric restriction and protein deficiency impair GH signaling in the liver. IGF-1 can fall below the normal range within 5-7 days of significant caloric restriction, even in people with intact pituitary function.
• Hypothyroidism: Thyroid hormone is required for normal GH receptor expression. Untreated hypothyroidism may suppress IGF-1 by 20-30% below baseline. [10]
• Poorly controlled type 1 diabetes: Chronic insulin deficiency impairs hepatic GH signaling. IGF-1 is often low in patients with HbA1c above 9% and improves with better glycemic control.

Pediatric Growth Failure

In children presenting with short stature or growth velocity below the 25th percentile, IGF-1 is a standard first-line test. A result below the age-adjusted reference range warrants GH stimulation testing. The Pediatric Endocrine Society recommends using two different GH stimulation tests before diagnosing pediatric GH deficiency, given the high false-positive rate of any single test. [11]

How IGF-1 Is Used to Monitor Peptide and GH Therapy

For patients on GH-axis therapies, including recombinant GH (somatropin), GHRH analogs (sermorelin, tesamorelin), and GH secretagogues (ipamorelin, CJC-1295), IGF-1 is the primary biomarker for dose titration. The treatment target for adult GH deficiency is IGF-1 within the age- and sex-adjusted normal range, specifically the middle third of the reference interval according to the Endocrine Society. Aiming higher than this range is not supported by current evidence and increases adverse effect risk. [8]

Starting a Monitoring Protocol

A practical IGF-1 monitoring schedule for patients on GH-axis therapy:

1. Baseline: Draw IGF-1 before starting any therapy.
2. 4-6 weeks after dose initiation or change: IGF-1 reflects accumulated GH exposure and will show the effect of a new dose within this window.
3. Every 6 months once stable: Annual minimum once target range is achieved.
4. Any time symptoms change: New joint pain, paresthesias, or edema warrant a prompt IGF-1 check regardless of schedule.

Tesamorelin and IGF-1 Monitoring

Tesamorelin (Egrifta), FDA-approved for HIV-associated lipodystrophy, raises IGF-1 as a consequence of increased GH pulsatility. In the Phase 3 LIPO trials (N=412), tesamorelin 2 mg/day raised mean IGF-1 from approximately 130 ng/mL to 230 ng/mL over 26 weeks, keeping most patients within the normal adult reference range. [12] About 10% of patients exceeded the upper limit of normal, which the prescribing information identifies as a reason for dose reduction or discontinuation.

Sermorelin and Ipamorelin

Off-label peptide protocols combining sermorelin or ipamorelin with CJC-1295 (a GHRH analog with drug affinity complex) are commonly used in longevity and men's health clinics. No large randomized trials have established optimal IGF-1 targets for these protocols. Clinicians generally apply the same Endocrine Society target range (mid-normal for age) used for somatropin, because the downstream hormone being monitored (IGF-1) is identical regardless of the upstream stimulus.

How to Raise or Lower IGF-1: Evidence-Based Interventions

Lifestyle Factors That Raise IGF-1

Resistance training is the most reliably documented lifestyle intervention. A meta-analysis of 22 randomized trials published in the Journal of Strength and Conditioning Research found that 8-16 weeks of progressive resistance training raised serum IGF-1 by a mean of 20.5 ng/mL (95% CI 8.3-32.7) compared to sedentary controls. [13] The effect was larger in older adults and in people with low baseline IGF-1.

Adequate protein intake supports IGF-1 production. Studies in older adults (65-80 years) show that protein intake above 1.2 g/kg/day is associated with higher IGF-1 compared to intakes below 0.8 g/kg/day. [14]

Optimized sleep matters because approximately 70% of daily GH secretion occurs during slow-wave sleep. Chronic sleep restriction to fewer than 6 hours per night may reduce IGF-1 by 10-15% over several weeks, based on controlled sleep restriction studies. [15]

Lifestyle and Dietary Factors That Lower IGF-1

Caloric restriction reliably lowers IGF-1. In the CALERIE Phase 2 trial (N=218), 25% caloric restriction over 24 months reduced IGF-1 by approximately 22% from baseline (P<0.001). [16] Whether this reduction reflects beneficial longevity signaling or nutritional inadequacy depends on the clinical context.

Prolonged fasting (greater than 48 hours) can suppress IGF-1 by 40-75% as the liver downregulates GH receptor expression in response to energy deficit. This effect reverses within days of refeeding.

High dietary fiber and plant-based diets have been associated with lower IGF-1 in observational studies. A cross-sectional analysis of 233 postmenopausal women found that vegan diets were associated with 13% lower IGF-1 compared to omnivore diets. [17]

Medical Interventions for High IGF-1

For pathologically elevated IGF-1 from acromegaly, three pharmacological classes are used:

• Somatostatin analogs (octreotide, lanreotide): First-line medical therapy. In pooled analyses, long-acting somatostatin analogs normalize IGF-1 in approximately 55-65% of patients. [5]
• Pegvisomant: A GH receptor antagonist that blocks IGF-1 production at the liver. Normalizes IGF-1 in over 90% of patients. [5]
• Cabergoline: A dopamine agonist with modest efficacy; normalizes IGF-1 in roughly 35% of patients when used as monotherapy. [1]

Getting the Most Accurate IGF-1 Result

Several pre-analytical factors affect IGF-1 values and should be accounted for before drawing or interpreting a result.

Timing and Sample Handling

IGF-1 does not require fasting, and values are stable across morning and evening draws. However, a few factors require attention:

• Acute illness or hospitalization: Critical illness and major surgery suppress IGF-1 acutely. A result drawn during hospitalization will be artificially low and cannot be used for baseline assessment.
• Recent vigorous exercise: Acute exercise may transiently raise IGF-1 for several hours. Drawing a sample within 2 hours of intense exercise may overestimate baseline.
• Estrogen route of administration: Women on oral estrogen should have their result interpreted knowing that oral estrogen may suppress IGF-1 by 15-25% compared to the transdermal route. [3]

Which Laboratory Platform to Use

Commercial assays for IGF-1 are not interchangeable. Quest Diagnostics, LabCorp, and Mayo Clinic Laboratories each use different immunoassay platforms with platform-specific reference intervals. If a patient is being monitored over time, serial IGF-1 measurements should be run on the same platform to avoid apparent changes from inter-assay variation alone.